Sweetened Roche Deal Stands A Real Chance

March 6 saw Swiss drugs giant Roche Pharmaceuticals increase its offer price for all outstanding Genentech shares to US$93 a unit, and extend the offer period, in its latest attempt to gain control of the US biotech firm. Roche Chairman Franz B. Humer said that 'based on conversations with Genentech shareholders, we believe that there is a strong sentiment to bring this process to a conclusion. As a result, we…will proceed quickly to complete all necessary financing [and] look forward to successfully completing the transaction.' CFW had previously predicted that a sweetened offer from Roche could still succeed (see 'A

To read the full article, please choose one of the following options: